Masimo Corp - MASI STOCK NEWS

Masimo (NASDAQ: MASI) announced findings from a study published in Pediatrics International, which evaluated the efficacy of its noninvasive PVi® technology in predicting fluid responsiveness for children aged 1-3 undergoing major neurosurgery. The study indicated that PVi and ∆Vpeak were effective predictors, while traditional pressure-based methods performed poorly. Out of 60 patients, 26 were identified as fluid responders, with baseline PVi showing a diagnostic accuracy AUROC of 0.775. This research highlights PVi's potential to enhance fluid management in pediatric surgery and underscores Masimo's commitment to improving outcomes for vulnerable patients.

Masimo (NASDAQ: MASI) has announced a strategic collaboration with Temple Health, focusing on remote patient monitoring and telehealth advancements. This partnership will explore the integration of Masimo's advanced technologies, including the W1™ health tracking watch and the Radius VSM™ patient monitor, to enhance healthcare delivery. They aim to improve health outcomes while raising awareness of health equity in Philadelphia. Both organizations will leverage their expertise to innovate and conduct joint clinical research. Notably, the W1™ and Radius VSM are awaiting FDA clearance, indicating potential future growth opportunities.

Masimo (NASDAQ: MASI) announced findings from a study published in the British Journal of Neurosurgery indicating that the noninvasive Pleth Variability Index (PVi) is as effective as the invasive stroke volume variation (SVV) for guiding intraoperative fluid management during neurosurgery. Conducted among 60 adult patients undergoing elective craniotomy, the study suggests PVi may be preferable given its noninvasive nature. Although fluid volume administered was higher in the SVV group (3208.3 mL vs. 2139.3 mL), other clinical outcomes like serum lactate and stay duration showed comparable results. CEO Joe Kiani emphasized PVi's cost-effectiveness and low risk.

Politan Capital Management, holding 9% of Masimo (NASDAQ: MASI), announced that the California State Teachers’ Retirement System (CalSTRS) has joined its lawsuit against the Company’s CEO Joe Kiani over his controversial employment agreement. The agreement may grant Mr. Kiani approximately $600 million if specific board changes occur, raising governance concerns. Critics argue this undermines shareholder rights and enables 'dead hand control' over future boards. A Delaware court recently criticized the agreement, noting the substantial payments tied to limited board changes.

Masimo (NASDAQ: MASI) announced its participation in the 44th Annual Raymond James Institutional Investors Conference on March 7, 2023, at 11:00 a.m. Eastern Time. Investors can access a live webcast of the presentation on the Masimo website, with a replay available afterward.

Masimo is a leading global medical technology company known for its innovative monitoring solutions, including the Masimo SET®, which has been shown to outperform other pulse oximetry technologies. The company aims to enhance patient outcomes and reduce healthcare costs through its advanced technologies.

Masimo reported strong financial results for Q4 and full-year 2022, with consolidated revenue reaching $617 million and $2,035.8 million respectively. The healthcare revenue was $351.9 million in Q4, growing 7.4% year-over-year, while full-year healthcare revenue hit $1,340.3 million with 8.2% growth. Non-healthcare revenue for Q4 was $265.1 million. The company achieved a GAAP net income of $41.1 million in Q4, or $0.76 per diluted share. For 2023, Masimo projects consolidated revenue between $2,415 million and $2,460 million, indicating continued growth.

Masimo (NASDAQ: MASI) announced findings from a study published in Medicine, showing that using the Oxygen Reserve Index (ORi™) alongside standard SpO₂ monitoring effectively reduced intraoperative hyperoxemia during laparoscopic gastrectomy. Conducted by Dr. Jin Hee Ahn and team, the study demonstrated significant differences in arterial oxygen levels; the SpO₂ group had a higher PaO₂ compared to the ORi-SpO₂ group one hour post-surgery (250.31 mmHg vs. 170.07 mmHg, p < .001). The severe hyperoxemia incidence was lower in the ORi-SpO₂ group at 16.7% vs. 84.4% for SpO₂.

Masimo (NASDAQ: MASI) announced that its Centroid wearable, wireless patient position and activity sensor received an Innovative Technology designation from Vizient, Inc., aimed at improving healthcare practices. Centroid helps prevent hospital-acquired pressure injuries (HAPIs), which affect 2.5 million patients annually in the U.S., with nearly 60,000 fatalities each year. It monitors patient position and movements using Bluetooth technology and integrates with the Masimo Root Patient Monitoring platform.

This recognition positions Masimo for potential growth in healthcare solutions, illustrating its commitment to enhancing patient outcomes and lowering care costs.

Masimo (NASDAQ: MASI) will announce its fourth quarter and FY 2022 financial results on February 28, 2023, after market closure. The results will be reviewed in a conference call at 1:30 p.m. PT (4:30 p.m. ET), hosted by CEO Joe Kiani and CFO Micah Young. Participants must register to obtain the dial-in details. Masimo specializes in medical technology, focusing on noninvasive monitoring solutions to enhance patient outcomes and reduce care costs. Their innovations include pulse oximetry and various blood monitoring technologies, widely used in leading healthcare institutions globally.